{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:37:29Z","timestamp":1792993049937,"version":"4.5.0"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Parkinson's disease (PD), a condition that involves neural degeneration,\ndevelops due to dopaminergic neuronal death in the substantia nigra pars compacta, resulting in reduced\nstriatal dopamine levels. This shortage causes problems with movement and thinking. The\nneurodefensive response of GLP-1 is especially important in PD. Assessments have demonstrated\nthe neuroprotective advantages of activating GLP-1 receptors in distinct models of PD, resulting\nin enhancements in motor as well as non-motor behaviour. These characteristics suggest that\nGLP-1 signalling could be a promising target for PD treatment. Moreover, plumbagin is the primary\nactive component of Plumbago zeylanica L., a medicinal herb that is clinically used in China.\nAlso, plumbagin is reported to have significant neuroprotective efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this study, male rats received rotenone (1.5 mg\/kg; subcutaneously), followed by\nplumbagin (20 mg\/kg; p.o.). The rats\u2019 motor abilities were assessed using the actophotometer,\nbeam walk, rotarod, gait analysis, open field, grip strength, as well as bar catalepsy evaluation. In\naddition, the levels of dopamine, RAGE, and GLP-1 were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Plumbagin improved movement issues caused by rotenone, boosted dopamine and\nGLP-1 levels, as well as lowered RAGE levels in the brains of rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The study highlights plumbagin\u2019s potential in treating PD by improving motor function,\nincreasing dopamine and GLP-1 levels, and reducing RAGE levels in a rotenone-induced rat\nmodel. These findings suggest that plumbagin may offer neuroprotective effects through GLP-1\npathway activation, making it a promising candidate for future PD therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These outcomes imply that agents that activate GLP-1, such as plumbagin, present a\npromising strategy for creating treatments to safeguard against rotenone-induced motor disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892037402724251006011830","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:58:06Z","timestamp":1761461886000},"page":"645-654","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like Peptide-1 Boosts Plumbagin\u2019s Neuroprotection Against Rotenone-Induced Motor Deficits"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4250-2282","authenticated-orcid":true,"given":"Aanchal","family":"Verma","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-9238","authenticated-orcid":true,"given":"Ahsas","family":"Goyal","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"23619","DOI":"10.1002\/jbt.23619","volume":"38","author":"Goyal A.","year":"2024","unstructured":"Goyal A.; Solanki K.; Verma A.; Luteolin: Nature\u2019s promising warrior against Alzheimer\u2019s and Parkinson\u2019s disease. J Biochem Mol Toxicol  2024,38(1),23619","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"14426","DOI":"10.1111\/cbdd.14426","volume":"103","author":"Verma A.","year":"2024","unstructured":"Verma A.; Chaudhary S.; Solanki K.; Goyal A.; Yadav H.N.; Exendin-4: A potential therapeutic strategy for Alzheimer\u2019s disease and Parkinson\u2019s disease. Chem Biol Drug Des  2024,103(1),14426","journal-title":"Chem Biol Drug Des"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Halliday G.M.; Brundin P.; Volkmann J.; Schrag A.E.; Lang A.E.; Parkinson disease. Nat Rev Dis Primers  2017,3(1),17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.expneurol.2005.01.013","volume":"193","author":"Hald A.","year":"2005","unstructured":"Hald A.; Lotharius J.; Oxidative stress and inflammation in Parkinson\u2019s disease: Is there a causal link? Exp Neurol  2005,193(2),279-290","journal-title":"Exp Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jnc.15890","volume":"168","author":"Gasparotto J.","year":"2024","unstructured":"Gasparotto J.; Somensi N.; Girardi C.S.; Bittencourt R.R.; de Oliveira L.M.; Hoefel L.P.; Scheibel I.M.; Peixoto D.O.; Moreira J.C.F.; Outeiro T.F.; Gelain D.P.; Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson\u2019s disease. J Neurochem  2024,168(8),1608-1624","journal-title":"J Neurochem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2174\/1389201025666230905092218","volume":"25","author":"Goyal A.","year":"2024","unstructured":"Goyal A.; Agrawal A.; Dubey N.; Verma A.; High mobility group box 1 protein: A plausible therapeutic molecular target in Parkinson\u2019s disease. Curr Pharm Biotechnol  2024,25(8),937-943","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Ben-Shlomo Y.","year":"2024","unstructured":"Ben-Shlomo Y.; Darweesh S.; Llibre-Guerra J.; Marras C.; San Luciano M.; Tanner C.; The epidemiology of Parkinson\u2019s disease. Lancet  2024,403(10423),283-292","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"Armstrong M.J.","year":"2020","unstructured":"Armstrong M.J.; Okun M.S.; Diagnosis and treatment of Parkinson disease: A review. JAMA  2020,323(6),548-560","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1185\/03007995.2010.549466","volume":"27","author":"Holst J.J.","year":"2011","unstructured":"Holst J.J.; Burcelin R.; Nathanson E.; Neuroprotective properties of GLP-1: Theoretical and practical applications. Curr Med Res Opin  2011,27(3),547-558","journal-title":"Curr Med Res Opin"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jdi.12464","volume":"7","author":"Katsurada K.","year":"2016","unstructured":"Katsurada K.; Yada T.; Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig  2016,7(Suppl 1),64-69","journal-title":"J Diabetes Investig"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"Pyke C.","year":"2014","unstructured":"Pyke C.; Heller R.S.; Kirk R.K.; \u00d8rskov C.; Reedtz-Runge S.; Kaastrup P.; Hvelplund A.; Bardram L.; Calatayud D.; Knudsen L.B.; GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology  2014,155(4),1280-1290","journal-title":"Endocrinology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","volume":"33","author":"Erbil D.","year":"2019","unstructured":"Erbil D.; Eren C.Y.; Demirel C.; K\u00fc\u00e7\u00fcker M.U.; Solaro\u011flu I.; Eser H.Y.; GLP-1\u2019s role in neuroprotection: A systematic review. Brain Inj  2019,33(6),734-819","journal-title":"Brain Inj"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMe2401743","volume":"390","author":"Standaert D.G.","year":"2024","unstructured":"Standaert D.G.; GLP-1, Parkinson\u2019s disease, and neuroprotection. N Engl J Med  2024,390(13),1233-1234","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.3390\/ijms25073812","volume":"25","author":"Kalinderi K.","year":"2024","unstructured":"Kalinderi K.; Papaliagkas V.; Fidani L.; GLP-1 receptor agonists: A new treatment in Parkinson\u2019s disease. Int J Mol Sci  2024,25(7),3812","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1515\/hsz-2021-0290","volume":"403","author":"Yadav A.M.","year":"2022","unstructured":"Yadav A.M.; Bagade M.M.; Ghumnani S.; Raman S.; Saha B.; Kubatzky K.F.; Ashma R.; The phytochemical plumbagin reciprocally modulates osteoblasts and osteoclasts. Biol Chem  2022,403(2),211-229","journal-title":"Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-3-319-41342-6_10","volume":"929","author":"Panichayupakaranant P.","year":"2016","unstructured":"Panichayupakaranant P.; Ahmad M.I.; Plumbagin and its role in chronic diseases. Adv Exp Med Biol  2016,929,229-246","journal-title":"Adv Exp Med Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5455\/jice.20160301094913","volume":"5","author":"Sukkasem N.","year":"2016","unstructured":"Sukkasem N.; Chatuphonprasert W.; Tatiyaaphiradee N.; Jarukamjorn K.; Imbalance of the antioxidative system by plumbagin and Plumbago indica L. extract induces hepatotoxicity in mice. J Intercult Ethnopharmacol  2016,5(2),137-145","journal-title":"J Intercult Ethnopharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.5114\/aoms.2016.64768","volume":"14","author":"Kuan-hong W.","year":"2018","unstructured":"Kuan-hong W.; Bai-zhou L.; Plumbagin protects against hydrogen peroxide-induced neurotoxicity by modulating NF-\u03baB and Nrf-2. Arch Med Sci  2018,14(5),1112-1118","journal-title":"Arch Med Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1097\/WNR.0000000000001103","volume":"29","author":"Wang S.","year":"2018","unstructured":"Wang S.; Zhang Z.; Zhao S.; Plumbagin inhibits amyloid-\u03b2-induced neurotoxicity. Neuroreport  2018,29(15),1269-1274","journal-title":"Neuroreport"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/jphp.12681","volume":"69","author":"Yuan J.H.","year":"2017","unstructured":"Yuan J.H.; Pan F.; Chen J.; Chen C.E.; Xie D.P.; Jiang X.Z.; Guo S.J.; Zhou J.; Neuroprotection by plumbagin involves BDNF-TrkB-PI3K\/Akt and ERK1\/2\/JNK pathways in isoflurane-induced neonatal rats. J Pharm Pharmacol  2017,69(7),896-906","journal-title":"J Pharm Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/molecules27061834","volume":"27","author":"Kumar Arora M.","year":"2022","unstructured":"Kumar Arora M.; Ratra A.; Asdaq S.M.B.; Alshamrani A.A.; Alsalman A.J.; Kamal M.; Tomar R.; Sahoo J.; Ashok J.; Imran M.; Plumbagin alleviates intracerebroventricular-quinolinic acid induced depression-like behavior and memory deficits in wistar rats. Molecules  2022,27(6),1834","journal-title":"Molecules"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1837278","DOI":"10.1155\/2022\/1837278","volume":"2022","author":"Su Y.","year":"2022","unstructured":"Su Y.; Li M.; Wang Q.; Xu X.; Qin P.; Huang H.; Zhang Y.; Zhou Y.; Yan J.; Inhibition of the TLR\/NF-\u03baB signaling pathway and improvement of autophagy mediates neuroprotective effects of plumbagin in Parkinson\u2019s disease. Oxid Med Cell Longev  2022,2022(1),1837278","journal-title":"Oxid Med Cell Longev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.sjbs.2017.03.006","volume":"25","author":"Chen X.J.","year":"2018","unstructured":"Chen X.J.; Zhang J.G.; Wu L.; Plumbagin inhibits neuronal apoptosis, intimal hyperplasia and also suppresses TNF-\u03b1\/NF-\u03baB pathway induced inflammation and matrix metalloproteinase-2\/9 expression in rat cerebral ischemia. Saudi J Biol Sci  2018,25(6),1033-1039","journal-title":"Saudi J Biol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1471-4159.2009.06552.x","volume":"112","author":"Son T.G.","year":"2010","unstructured":"Son T.G.; Camandola S.; Arumugam T.V.; Cutler R.G.; Telljohann R.S.; Mughal M.R.; Moore T.A.; Luo W.; Yu Q.S.; Johnson D.A.; Johnson J.A.; Greig N.H.; Mattson M.P.; Plumbagin, a novel Nrf2\/ARE activator, protects against cerebral ischemia. J Neurochem  2010,112(5),1316-1326","journal-title":"J Neurochem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.pharep.2017.02.006","volume":"69","author":"Arruri V.","year":"2017","unstructured":"Arruri V.; Komirishetty P.; Areti A.; Dungavath S.K.N.; Kumar A.; Nrf2 and NF-\u03baB modulation by Plumbagin attenuates functional, behavioural and biochemical deficits in rat model of neuropathic pain. Pharmacol Rep  2017,69(4),625-632","journal-title":"Pharmacol Rep"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jneuroim.2014.05.014","volume":"273","author":"Zhang K.","year":"2014","unstructured":"Zhang K.; Ge Z.; Da Y.; Wang D.; Liu Y.; Xue Z.; Li Y.; Li W.; Zhang L.; Wang H.; Zhang H.; Peng M.; Hao J.; Yao Z.; Zhang R.; Plumbagin suppresses dendritic cell functions and alleviates experimental autoimmune encephalomyelitis. J Neuroimmunol  2014,273(1-2),42-52","journal-title":"J Neuroimmunol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.5114\/fn.2019.89857","volume":"57","author":"Radad K.","year":"2019","unstructured":"Radad K.; Al-Shraim M.; Al-Emam A.; Wang F.; Kranner B.; Rausch W.D.; Moldzio R.; Rotenone: From modelling to implication in Parkinson\u2019s disease. Folia Neuropathol  2019,57(4),317-326","journal-title":"Folia Neuropathol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/9191284","volume":"2022","author":"Liang W.","year":"2022","unstructured":"Liang W.; Yao L.; Chen J.; Chen Z.; Wu X.; Huang X.; Therapeutic and neuroprotective effects of Bushen Jianpi decoction on a rotenone-induced rat model of Parkinson\u2019s disease. Evid Based Complement Alternat Med  2022,2022,1-15","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","volume":"34","author":"Cannon J.R.","year":"2009","unstructured":"Cannon J.R.; Tapias V.; Na H.M.; Honick A.S.; Drolet R.E.; Greenamyre J.T.; A highly reproducible rotenone model of Parkinson\u2019s disease. Neurobiol Dis  2009,34(2),279-290","journal-title":"Neurobiol Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0006-8993(00)02960-7","volume":"885","author":"Thiffault C.","year":"2000","unstructured":"Thiffault C.; Langston J.W.; Di Monte D.A.; Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res  2000,885(2),283-288","journal-title":"Brain Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbr.2004.12.008","volume":"160","author":"Henderson J.M.","year":"2005","unstructured":"Henderson J.M.; Stanic D.; Tomas D.; Patch J.; Horne M.K.; Bourke D.; Finkelstein D.I.; Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys. Behav Brain Res  2005,160(2),267-276","journal-title":"Behav Brain Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10571-015-0230-6","volume":"36","author":"Kiasalari Z.","year":"2016","unstructured":"Kiasalari Z.; Baluchnejadmojarad T.; Roghani M.; Hypericum perforatum hydroalcoholic extract mitigates motor dysfunction and is neuroprotective in intrastriatal 6-hydroxydopamine rat model of Parkinson\u2019s disease. Cell Mol Neurobiol  2016,36(4),521-530","journal-title":"Cell Mol Neurobiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21608\/smj.2020.21596.1089","volume":"24","author":"hegab","year":"2020","unstructured":"hegab ; Ahmed O.; Mahmoud M.; Abdelhamid A.; Behavioral evaluation of rotenone model of parkinson\u2019s disease in male wistar rats. Sohag Med J  2020,24(2),8-14","journal-title":"Sohag Med J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12017-019-08590-2","volume":"22","author":"Garabadu D.","year":"2020","unstructured":"Garabadu D.; Agrawal N.; Naringin exhibits neuroprotection against rotenone-induced neurotoxicity in experimental rodents. Neuromolecular Med  2020,22(2),314-330","journal-title":"Neuromolecular Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s43450-022-00277-3","volume":"32","author":"Verma A.","year":"2022","unstructured":"Verma A.; Goyal A.; Reformative effect of daidzein on motor dysfunction following rotenone injection in ovariectomized rats. Rev Bras Farmacogn  2022,32(4),563-574","journal-title":"Rev Bras Farmacogn"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"117271","DOI":"10.1016\/j.bone.2024.117271","volume":"190","author":"Knani L.","year":"2025","unstructured":"Knani L.; Venditti M.; Rouis H.; Minucci S.; Messaoudi I.; Effects of dopaminergic neuron degeneration on osteocyte apoptosis and osteogenic markers in 6-OHDA male rat model of Parkinson\u2019s disease. Bone  2025,190,117271","journal-title":"Bone"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1177\/0269881110364269","volume":"25","author":"Kumar P.","year":"2011","unstructured":"Kumar P.; Kalonia H.; Kumar A.; Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington\u2019s-like symptoms: A comparative study. J Psychopharmacol  2011,25(10),1399-1411","journal-title":"J Psychopharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/942981","volume":"2012","author":"Agrawal S.S.","year":"2012","unstructured":"Agrawal S.S.; Gullaiya S.; Dubey V.; Singh V.; Kumar A.; Nagar A.; Tiwari P.; Neurodegenerative shielding by curcumin and its derivatives on brain lesions induced by 6-OHDA model of Parkinson\u2019s disease in albino wistar rats. Cardiovasc Psychiatry Neurol  2012,2012,1-8","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/01480545.2021.1907909","volume":"45","author":"Raj K.","year":"2022","unstructured":"Raj K.; Gupta G.D.; Singh S.; L-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson\u2019s disease. Drug Chem Toxicol  2022,45(5),2097-2108","journal-title":"Drug Chem Toxicol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneumeth.2005.04.005","volume":"148","author":"Ferro M.M.","year":"2005","unstructured":"Ferro M.M.; Bellissimo M.I.; Anselmo-Franci J.A.; Angellucci M.E.M.; Canteras N.S.; Da Cunha C.; Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson\u2019s disease: Histological, neurochemical, motor and memory alterations. J Neurosci Methods  2005,148(1),78-87","journal-title":"J Neurosci Methods"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bbr.2006.04.004","volume":"171","author":"Karl T.","year":"2006","unstructured":"Karl T.; Duffy L.; Obrien E.; Matsumoto I.; Dedova I.; Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behav Brain Res  2006,171(2),286-294","journal-title":"Behav Brain Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.2116\/analsci.25.1451","volume":"25","author":"Guo L.","year":"2009","unstructured":"Guo L.; Zhang Y.; Li Q.; Spectrophotometric determination of dopamine hydrochloride in pharmaceutical, banana, urine and serum samples by potassium ferricyanide-Fe(III). Anal Sci  2009,25(12),1451-1455","journal-title":"Anal Sci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43088-019-0007-y","volume":"8","author":"Gopi C.","year":"2019","unstructured":"Gopi C.; Sastry V.G.; Dhanaraju M.D.; Effect of novel phenothiazine derivatives on brain dopamine in wistar rats. Beni Suef Univ J Basic Appl Sci  2019,8,1-9","journal-title":"Beni Suef Univ J Basic Appl Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"100439","DOI":"10.1016\/j.prmcm.2024.100439","volume":"11","author":"Famusiwa C.D.","year":"2024","unstructured":"Famusiwa C.D.; Josiah S.S.; Saliu I.O.; Fatoki T.H.; Umar H.I.; Akinmoladun A.C.; Taxifolin alleviate metabolic and neurochemical alterations in the hippocampus and cortex of rats with rotenone-induced toxicity: In vivo and in silico insight. Pharmacol Res Mod Chin Med  2024,11,100439","journal-title":"Pharmacol Res Mod Chin Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1179\/135100004225005976","volume":"9","author":"Tilak J.C.","year":"2004","unstructured":"Tilak J.C.; Adhikari S.; Devasagayam T.P.A.; Antioxidant properties of Plumbago zeylanica, an Indian medicinal plant and its active ingredient, plumbagin. Redox Rep  2004,9(4),219-227","journal-title":"Redox Rep"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/jcb.22620","volume":"110","author":"Checker R.","year":"2010","unstructured":"Checker R.; Sharma D.; Sandur S.K.; Subrahmanyam G.; Krishnan S.; Poduval T.B.; Sainis K.B.; Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols. J Cell Biochem  2010,110(5),1082-1093","journal-title":"J Cell Biochem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1471-4159.2010.06780.x","volume":"115","author":"Luo Y.","year":"2010","unstructured":"Luo Y.; Mughal M.R.; Ouyang T.G.S.X.; Jiang H.; Luo W.; Yu Q.S.; Greig N.H.; Mattson M.P.; Plumbagin promotes the generation of astrocytes from rat spinal cord neural progenitors via activation of the transcription factor Stat3. J Neurochem  2010,115(6),1337-1349","journal-title":"J Neurochem"},{"key":"ref=48","author":"Verma A.","year":"2024","unstructured":"Verma A.; Goyal A.; Plumbagin\u2019s healing effect on motor impairment in rotenone-toxified rodents. Curr Neurovasc Res  2024","journal-title":"Curr Neurovasc Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"176936","DOI":"10.1016\/j.ejphar.2024.176936","volume":"982","author":"Verma A.","year":"2024","unstructured":"Verma A.; Goyal A.; Beyond insulin: The intriguing role of GLP-1 in Parkinson\u2019s disease. Eur J Pharmacol  2024,982,176936","journal-title":"Eur J Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/19390211.2016.1275916","volume":"14","author":"Khadrawy Y.A.","year":"2017","unstructured":"Khadrawy Y.A.; Salem A.M.; El-Shamy K.A.; Ahmed E.K.; Fadl N.N.; Hosny E.N.; Neuroprotective and therapeutic effect of caffeine on the rat model of Parkinson\u2019s disease induced by rotenone. J Diet Suppl  2017,14(5),553-572","journal-title":"J Diet Suppl"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3390\/ijms21072464","volume":"21","author":"Chia S.J.","year":"2020","unstructured":"Chia S.J.; Tan E.K.; Chao Y.X.; Historical perspective: Models of Parkinson\u2019s disease. Int J Mol Sci  2020,21(7),2464","journal-title":"Int J Mol Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuint.2005.12.016","volume":"49","author":"Saravanan K.S.","year":"2006","unstructured":"Saravanan K.S.; Sindhu K.M.; Senthilkumar K.S.; Mohanakumar K.P.; l-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int  2006,49(1),28-40","journal-title":"Neurochem Int"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jnc.13087","volume":"133","author":"Abdelsalam R.M.","year":"2015","unstructured":"Abdelsalam R.M.; Safar M.M.; Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: Role of RAGE-NF\u03baB and Nrf2-antioxidant signaling pathways. J Neurochem  2015,133(5),700-707","journal-title":"J Neurochem"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892037402724251006011830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/246484\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892037402724251006011830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:17:15Z","timestamp":1792991835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/246484\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892037402724251006011830","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}